Plasma parathyroid hormone and cardiovascular disease in treatment-naive patients with primary hyperparathyroidism: The EPATH trial

Patients with primary hyperparathyroidism are at increased risk for high blood pressure, vascular stiffening, and left ventricular hypertrophy, but previous studies have failed to demonstrate the direct associations with circulating parathyroid hormone (PTH) levels. The authors investigated cross-se...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Wetzel, Julia (VerfasserIn) , März, Winfried (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 20 August 2017
In: The journal of clinical hypertension
Year: 2017, Jahrgang: 19, Heft: 11, Pages: 1173-1180
ISSN:1751-7176
DOI:10.1111/jch.13064
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1111/jch.13064
Verlag, Volltext: http://onlinelibrary.wiley.com/doi/abs/10.1111/jch.13064
Volltext
Verfasserangaben:Julia Wetzel, Stefan Pilz, Martin R. Grübler, Astrid Fahrleitner‐Pammer, Hans P. Dimai, Dirk von Lewinski, Ewald Kolesnik, Sabine Perl, Christian Trummer, Verena Schwetz, Andreas Meinitzer, Evgeny Belyavskiy, Jakob Völkl, Cristiana Catena, Vincent Brandenburg, Winfried März, Burkert Pieske, Helmut Brussee, Andreas Tomaschitz, Nicolas D. Verheyen

MARC

LEADER 00000caa a2200000 c 4500
001 1580083153
003 DE-627
005 20230427065643.0
007 cr uuu---uuuuu
008 180815s2017 xx |||||o 00| ||eng c
024 7 |a 10.1111/jch.13064  |2 doi 
035 |a (DE-627)1580083153 
035 |a (DE-576)510083153 
035 |a (DE-599)BSZ510083153 
035 |a (OCoLC)1341017079 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Wetzel, Julia  |e VerfasserIn  |0 (DE-588)1164544128  |0 (DE-627)1028970250  |0 (DE-576)510083218  |4 aut 
245 1 0 |a Plasma parathyroid hormone and cardiovascular disease in treatment-naive patients with primary hyperparathyroidism  |b The EPATH trial  |c Julia Wetzel, Stefan Pilz, Martin R. Grübler, Astrid Fahrleitner‐Pammer, Hans P. Dimai, Dirk von Lewinski, Ewald Kolesnik, Sabine Perl, Christian Trummer, Verena Schwetz, Andreas Meinitzer, Evgeny Belyavskiy, Jakob Völkl, Cristiana Catena, Vincent Brandenburg, Winfried März, Burkert Pieske, Helmut Brussee, Andreas Tomaschitz, Nicolas D. Verheyen 
264 1 |c 20 August 2017 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 15.08.2018 
520 |a Patients with primary hyperparathyroidism are at increased risk for high blood pressure, vascular stiffening, and left ventricular hypertrophy, but previous studies have failed to demonstrate the direct associations with circulating parathyroid hormone (PTH) levels. The authors investigated cross-sectional relationships between PTH and 24-hour pulse wave velocity, nocturnal systolic blood pressure, and left ventricular mass index in patients with primary hyperparathyroidism who were treatment-naive with cinacalcet, renin-angiotensin-aldosterone-system inhibitors, and thiazide or loop diuretics. In 76 patients, mean±SD of pulse wave velocity, nocturnal systolic blood pressure, and left ventricular mass index values were 9.3±1.8 m/s, 116.6±17.0 mm Hg, and 92.8±23.0 g/m². In multivariate linear regression analyses with adjustment for potentially confounding parameters, PTH was independently associated with nocturnal systolic blood pressure (adjusted ß coefficient=.284, P=.040), mean 24-hour pulse wave velocity (ß=.199, P=.001), and left ventricular mass index (ß=.252, P=.025). PTH may promote vascular and cardiac remodeling in primary hyperparathyroidism. Interventional trials are needed to test the antihypertensive and cardioprotective effects of PTH-inhibitory treatment strategies. 
650 4 |a ambulatory blood pressure monitoring 
650 4 |a blood pressure 
650 4 |a left ventricular mass 
650 4 |a parathyroid hormone 
650 4 |a primary hyperparathyroidism 
650 4 |a pulse wave velocity 
700 1 |a März, Winfried  |d 1958-  |e VerfasserIn  |0 (DE-588)1027603599  |0 (DE-627)729463605  |0 (DE-576)373454635  |4 aut 
773 0 8 |i Enthalten in  |t The journal of clinical hypertension  |d Hoboken, NJ : Wiley, 2001  |g 19(2017), 11, Seite 1173-1180  |h Online-Ressource  |w (DE-627)334928443  |w (DE-600)2058690-5  |w (DE-576)306829657  |x 1751-7176  |7 nnas  |a Plasma parathyroid hormone and cardiovascular disease in treatment-naive patients with primary hyperparathyroidism The EPATH trial 
773 1 8 |g volume:19  |g year:2017  |g number:11  |g pages:1173-1180  |g extent:8  |a Plasma parathyroid hormone and cardiovascular disease in treatment-naive patients with primary hyperparathyroidism The EPATH trial 
856 4 0 |u http://dx.doi.org/10.1111/jch.13064  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u http://onlinelibrary.wiley.com/doi/abs/10.1111/jch.13064  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20180815 
993 |a Article 
994 |a 2017 
998 |g 1027603599  |a März, Winfried  |m 1027603599:März, Winfried  |d 60000  |d 61400  |e 60000PM1027603599  |e 61400PM1027603599  |k 0/60000/  |k 1/60000/61400/  |p 16 
999 |a KXP-PPN1580083153  |e 302242065X 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"role":"aut","display":"Wetzel, Julia","given":"Julia","family":"Wetzel"},{"role":"aut","display":"März, Winfried","given":"Winfried","family":"März"}],"language":["eng"],"relHost":[{"recId":"334928443","titleAlt":[{"title":"The JCH"}],"origin":[{"publisher":"Wiley ; Mescape ; Blackwell ; Wiley-Blackwell","dateIssuedDisp":"2001-","publisherPlace":"Hoboken, NJ ; Hillsboro, Or. ; Oxford [u.a.] ; Oxford [u.a.]","dateIssuedKey":"2001"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"doi":["10.1111/(ISSN)1751-7176"],"eki":["334928443"],"zdb":["2058690-5"],"issn":["1751-7176"]},"part":{"volume":"19","extent":"8","year":"2017","issue":"11","pages":"1173-1180","text":"19(2017), 11, Seite 1173-1180"},"pubHistory":["Nachgewiesen 3.2001 -"],"disp":"Plasma parathyroid hormone and cardiovascular disease in treatment-naive patients with primary hyperparathyroidism The EPATH trialThe journal of clinical hypertension","note":["Gesehen am 08.04.2021","Erscheint monatlich, früher alle zwei Monate","Fortsetzung der Druck-Ausgabe"],"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"the JCH : official journal of the World Hypertension League","title":"The journal of clinical hypertension","title_sort":"journal of clinical hypertension"}]}],"title":[{"title":"Plasma parathyroid hormone and cardiovascular disease in treatment-naive patients with primary hyperparathyroidism","subtitle":"The EPATH trial","title_sort":"Plasma parathyroid hormone and cardiovascular disease in treatment-naive patients with primary hyperparathyroidism"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"eki":["1580083153"],"doi":["10.1111/jch.13064"]},"physDesc":[{"extent":"8 S."}],"note":["Gesehen am 15.08.2018"],"name":{"displayForm":["Julia Wetzel, Stefan Pilz, Martin R. Grübler, Astrid Fahrleitner‐Pammer, Hans P. Dimai, Dirk von Lewinski, Ewald Kolesnik, Sabine Perl, Christian Trummer, Verena Schwetz, Andreas Meinitzer, Evgeny Belyavskiy, Jakob Völkl, Cristiana Catena, Vincent Brandenburg, Winfried März, Burkert Pieske, Helmut Brussee, Andreas Tomaschitz, Nicolas D. Verheyen"]},"recId":"1580083153","origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"20 August 2017"}]} 
SRT |a WETZELJULIPLASMAPARA2020